Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
34
GBIO Quote, Financials, Valuation and Earnings
Last price:
$5.51
Seasonality move
:
-14.66%
Day range:
$5.50 - $5.77
52-week range:
$3.00 - $12.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
8.10x
P/B ratio:
0.75x
Volume:
46.8K
Avg. volume:
58.5K
1-year change:
-46.42%
Market cap:
$38.1M
Revenue:
$19.9M
EPS (TTM):
-$7.36
Analysts' Opinion
-
Consensus RatingGeneration Bio Co. has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.83, Generation Bio Co. has an estimated upside of 20.31% from its current price of $5.68.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $5.68.
Fair Value
-
According to the consensus of 4 analysts, Generation Bio Co. has 20.31% upside to fair value with a price target of $6.83 per share.
GBIO vs. S&P 500
-
Over the past 5 trading days, Generation Bio Co. has overperformed the S&P 500 by 5.12% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Generation Bio Co. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Generation Bio Co. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Generation Bio Co. reported revenues of $1.6M.
Earnings Growth
-
Generation Bio Co. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Generation Bio Co. reported earnings per share of -$0.82.
Enterprise value:
-25.5M
EV / Invested capital:
--
Price / LTM sales:
8.10x
EV / EBIT:
--
EV / Revenue:
-1.67x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
0.22x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$10.4M
Return On Assets:
-31.87%
Net Income Margin (TTM):
-410.13%
Return On Equity:
-84.94%
Return On Invested Capital:
-41.48%
Operating Margin:
-1348.68%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $3M | $18.6M | $15.3M | $7.6M | $1.6M | |
| Gross Profit | -$2.3M | $13.5M | $10.4M | $6.4M | $190K | |
| Operating Income | -$135.1M | -$90.2M | -$78.3M | -$16.7M | -$21.5M | |
| EBITDA | -$129.8M | -$85.1M | -$73.4M | -$15.5M | -$20.1M | |
| Diluted EPS | -$1.98 | -$2.19 | -$7.36 | -$0.23 | -$0.82 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $403.3M | $310.6M | $297.8M | $191.3M | $93.5M | |
| Total Assets | $464M | $402.8M | $381.5M | $248.8M | $121.9M | |
| Current Liabilities | $14.5M | $17.3M | $32.8M | $30.2M | $21M | |
| Total Liabilities | $56.8M | $94.1M | $149.6M | $144.3M | $71.3M | |
| Total Equity | $407.2M | $308.7M | $231.9M | $104.4M | $50.6M | |
| Total Debt | $42.3M | $76.7M | $71M | $83M | $19.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$50.8M | -$97.8M | -$113.7M | -$19.5M | -$52.7M | |
| Cash From Investing | -$26.2M | $22.3M | $113.7M | $12.7M | $25.5M | |
| Cash From Financing | $35.8M | $183K | $215K | -$3K | -$2K | |
| Free Cash Flow | -$54.3M | -$104.4M | -$114.7M | -$19.6M | -$52.7M | |
GBIO
Sector
Market Cap
$38.1M
$28.1M
Price % of 52-Week High
45.81%
50%
Dividend Yield
0%
0%
Shareholder Yield
32.52%
-1.54%
1-Year Price Total Return
-46.42%
-17.67%
Beta (5-Year)
2.047
0.503
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$5.57
200-day SMA
Buy
Level
$4.90
Bollinger Bands (100)
Sell
Level
5.21 - 6.27
Chaikin Money Flow
Buy
Level
2.7M
20-day SMA
Buy
Level
$5.43
Relative Strength Index (RSI14)
Buy
Level
60.34
ADX Line
Buy
Level
16.95
Williams %R
Sell
Level
-15.7922
50-day SMA
Buy
Level
$5.48
MACD (12, 26)
Buy
Level
0.06
25-day Aroon Oscillator
Buy
Level
84
On Balance Volume
Neutral
Level
15.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.1763)
Sell
CA Score
(Annual)
Level (-1.7091)
Buy
Beneish M-Score
(Annual)
Level (-2.5018)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (3.6723)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA, a novel cell-targeted lipid nanoparticle delivery system, or ctLNP, and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.
Stock Forecast FAQ
In the current month, GBIO has received 1 Buy ratings 3 Hold ratings, and 0 Sell ratings. The GBIO average analyst price target in the past 3 months is $6.83.
-
Where Will Generation Bio Co. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Generation Bio Co. share price will rise to $6.83 per share over the next 12 months.
-
What Do Analysts Say About Generation Bio Co.?
Analysts are divided on their view about Generation Bio Co. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Generation Bio Co. is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is Generation Bio Co.'s Price Target?
The price target for Generation Bio Co. over the next 1-year time period is forecast to be $6.83 according to 4 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is GBIO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Generation Bio Co. is a Hold. 3 of 4 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of GBIO?
You can purchase shares of Generation Bio Co. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Generation Bio Co. shares.
-
What Is The Generation Bio Co. Share Price Today?
Generation Bio Co. was last trading at $5.51 per share. This represents the most recent stock quote for Generation Bio Co.. Yesterday, Generation Bio Co. closed at $5.68 per share.
-
How To Buy Generation Bio Co. Stock Online?
In order to purchase Generation Bio Co. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get GBIO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GBIO
Sector
P/E ratio
--
23.88x
PEG ratio
0.00x
-0.01x
P/B ratio
0.75x
1.82x
Price / LTM sales
8.10x
1.59x
Growth Metrics
GBIO
Sector
Revenue growth
-78.9%
4.73%
Earnings growth
-257.24%
11.11%
Revenue (5-year growth)
177.31%
6.46%
Earnings forecast
-$2.67
-$0.18
Profitability
GBIO
Sector
Profitability FY 2024
$15M
$3.6M
Return on invested capital
-41.48%
-31.77%
Return on assets
-31.87%
-28.18%
Return on equity
-84.94%
-37.47%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Mar
12
Estimated Next Earnings Date
Feb
4
Balance Sheet
GBIO
Sector
Total cash
$89.6M
$26.3M
Short term investments
$108.9M
$26M
Total assets
$231.2M
$76.9M
Long term debt
$19.7M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 2
Corcept Therapeutics, Inc. [CORT] is up 5.11% over the past day.
Buy
75
AXSM alert for Jan 2
Axsome Therapeutics, Inc. [AXSM] is down 3.83% over the past day.
Sell
50
NUTX alert for Jan 2
Nutex Health, Inc. [NUTX] is down 9.63% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
